New Australian Drug

[Drphil1938]

The following link is about a new drug developed in Australia that will keep cancer from metastasizing. I found this quite interesting and I am hopeful. If some of us go into remission it may help us stay there.

newatlas.com/medical/new-dr...

[Drphil1938]

The name is not given in the article. If you go to the link above the name of the developing group is given.

[Grumpyswife]

Veyonda

[Manilo in reply to Grumpyswife]

Veyonda is developed by Noxopharm.

They expect to do phase 3 trials this year with Lu177 + Veyonda.

Veyonda seems to enhance the abscopal effect.

[hansjd in reply to Manilo]

Sorry, but I don't think this drug is Veyonda. That's being developed by Noxopharm as you said. They're based in Sydney, NSW. Veyonda does seem to be a drug with great potential and a lot further along the path to clinical use.

This drug is being developed at the Harry Perkins Institute of Medical Research at Murdoch in Perth WA. It's still very much in the experimental stage but does sound promising.

Go OZ! Kind of appropriate given this is Australia Day (well the holiday anyway).

[marnieg46 in reply to hansjd]

Hi hansjd...yes go OZ. Nothing whatsoever to do about PC but certainly to do with the Aussie spirit of 'we can do it'...'there is an answer'. So if you haven't seen this item in weekend's paper thought you'd like to check off the 42 distinguishing features of being an Aussie .....no offence to our USA friends!

smh.com.au/entertainment/tv...

[hansjd in reply to marnieg46]

OMG I laughed out loud so many times. Thanks for that . Made my day : ) G

PS our car goes to Bunnings automatically, even when we aren't planning to go there. lol.

[marnieg46 in reply to hansjd]

So glad you liked it...I went to Bunnings yesterday to get some sugar cane mulch....just seemed like the place to be on Australia Day! M

[hansjd in reply to Manilo]

Link to the article

"Remodeling of Metastatic Vasculature Reduces Lung Colonization and Sensitizes Overt Metastases to Immunotherapy" published in Cell Reports is:

cell.com/cell-reports/home

It's the first article, top of the home page.

Summary

Due to limited current therapies, metastases are the primary cause of mortality in cancer patients. Here, we employ a fusion compound of the cytokine LIGHT and a vascular targeting peptide (LIGHT-VTP) that homes to angiogenic blood vessels in primary tumors. We show in primary mouse lung cancer that normalization of tumor vasculature by LIGHT-VTP prevents cancer cell intravasation. Further, LIGHT-VTP efficiently targets pathological blood vessels in the pre-metastatic niche, reducing vascular hyper-permeability and extracellular matrix (ECM) deposition, thus blocking metastatic lung colonization. Moreover, we demonstrate that mouse and human metastatic melanoma deposits are targetable by VTP. In overt melanoma metastases, LIGHT-VTP normalizes intra-metastatic blood vessels and increases GrzB+ effector T cells. Successful treatment induces high endothelial venules (HEVs) and lymphocyte clusters, which sensitize refractory lung metastases to anti-PD-1 checkpoint inhibitors. These findings demonstrate an important application for LIGHT-VTP therapy in preventing metastatic development as well as exerting anti-tumor effects in established metastases.